drugset / Trial / NCT01474382

Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients

NCT01474382

Phase 4 Completed 150 enrolled Novocol Pharmaceutical of Canada, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether OraVerse is safe and effective for the reversal of dental anesthesia in children 2 to 5 years of age weighing at least 10 kg.

Timeline

Start
2012-02
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Phentolamine Small molecule 0.45 ml
Subject Phentolamine Small molecule 0.9 ml
Subject Phentolamine Small molecule 1.8 ml

Indications

No indication recorded.